C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells

BACKGROUND: Tamoxifen is a frontline therapy for estrogen receptor (ER)-positive breast cancer in premenopausal women. However, many patients develop resistance to tamoxifen, and the mechanism underlying tamoxifen resistance is not well understood. Here we examined whether ER-c-Src-HER2 complex form...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wei, Xu, Ling, Che, Xiaofang, Li, Haizhou, Zhang, Ye, Song, Na, Wen, Ti, Hou, Kezuo, Yang, Yi, Zhou, Lu, Xin, Xing, Xu, Lu, Zeng, Xue, Shi, Sha, Liu, Yunpeng, Qu, Xiujuan, Teng, Yuee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930956/
https://www.ncbi.nlm.nih.gov/pubmed/29720121
http://dx.doi.org/10.1186/s12885-018-4387-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930956/
https://www.ncbi.nlm.nih.gov/pubmed/29720121
http://dx.doi.org/10.1186/s12885-018-4387-5

Ejemplares similares